StockData
Palisade Bio, Inc. logo

Palisade Bio, Inc. (PALI) stock

PALINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.12−0.02 (-1.75%)

Close on Nov 13, 2026Market cap $195.18MP/E –Yield –

Palisade Bio operating margin

Operating margin is operating income as a percentage of revenue.

Palisade Bio's operating margin for the twelve months ending Sep 30, 2026 was -9625.4%. For fiscal 2023 it was -5228.0%, against -68764.8% the year before. The highest annual figure on record is -2070.4% in fiscal 2010.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 2023-5228.0%+63536.8
FY2020Dec 31, 2020-68764.8%−12693.0
FY2019Dec 31, 2019-56071.8%−52895.1
FY2018Dec 31, 2018-3176.7%+1941.4
FY2017Dec 31, 2017-5118.1%+121909.1
FY2016Dec 31, 2016-127027.2%+56869.6
FY2015Dec 31, 2015-183896.8%−91315.4
FY2014Dec 31, 2014-92581.4%−81196.0
FY2013Dec 31, 2013-11385.4%−8894.3
FY2012Dec 31, 2012-2491.1%+834.5
FY2011Dec 31, 2011-3325.6%−1255.2
FY2010Dec 31, 2010-2070.4%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-2339.6%+71300.4
Q1 FY2023Mar 31, 2023-1011.6%+32052.6
Q4 FY2020Dec 31, 2020-129800.0%−44497.1
Q3 FY2020Sep 30, 2020-72640.0%+12327.0
Q2 FY2020Jun 30, 2020-73640.0%−49338.2
Q1 FY2020Mar 31, 2020-33064.2%+65198.4
Q4 FY2019Dec 31, 2019-85302.9%−13110.3
Q3 FY2019Sep 30, 2019-84967.0%−1660.0
Q2 FY2019Jun 30, 2019-24301.8%−23500.6
Q1 FY2019Mar 31, 2019-98262.6%−4302.8
Q4 FY2018Dec 31, 2018-72192.6%−71294.0
Q3 FY2018Sep 30, 2018-83307.0%+20208.0
Q2 FY2018Jun 30, 2018-801.2%+167928.1
Q1 FY2018Mar 31, 2018-93959.8%+75320.5
Q4 FY2017Dec 31, 2017-898.6%+63724.7
Q3 FY2017Sep 30, 2017-103514.9%–
Q2 FY2017Jun 30, 2017-168729.2%–
Q1 FY2017Mar 31, 2017-169280.3%–
Q4 FY2016Dec 31, 2016-64623.3%–

More Palisade Bio figures

See a number that looks wrong?